AANEM Action Center

1-6 of 6

• 

  RestartResume

  Individualizing gMG Treatment: Defining Success With Each Patient

  RestartResume

  Individualizing gMG Treatment: Defining Success With Each Patient

  NeuroFrontiers

  Individualizing gMG Treatment: Defining Success With Each Patient

  Omar Sinno, MD

  • 

    

    Omar Sinno, MD

• 

  RestartResume

  Optimizing Generalized Myasthenia Gravis Care Through Patient-Centered Choices

  RestartResume

  Optimizing Generalized Myasthenia Gravis Care Through Patient-Centered Choices

  NeuroFrontiers

  Optimizing Generalized Myasthenia Gravis Care Through Patient-Centered Choices

  Sheetal Shroff, MD

  • 

    

    Sheetal Shroff, MD

• 

  RestartResume

  Timing Meningococcal Vaccines in gMG: Challenges and Considerations

  RestartResume

  Timing Meningococcal Vaccines in gMG: Challenges and Considerations

  NeuroFrontiers

  Timing Meningococcal Vaccines in gMG: Challenges and Considerations

  Michael Weiss, MD

  • 

    

    Michael Weiss, MD

• 

  RestartResume

  Examining Inebilizumab in Generalized Myasthenia Gravis: Insights from MINT

  RestartResume

  Examining Inebilizumab in Generalized Myasthenia Gravis: Insights from MINT

  NeuroFrontiers

  Examining Inebilizumab in Generalized Myasthenia Gravis: Insights from MINT

  Ryan Quigley

  • 

    

    Ryan Quigley

• 

  RestartResume

  Advancements in gMG Management: Zilucoplan as an Alternative to C5 Inhibitors

  RestartResume

  Advancements in gMG Management: Zilucoplan as an Alternative to C5 Inhibitors

  NeuroFrontiers

  Advancements in gMG Management: Zilucoplan as an Alternative to C5 Inhibitors

• 

  RestartResume

  LUMINESCE: Assessing Satralizumab in Generalized Myasthenia Gravis

  RestartResume

  LUMINESCE: Assessing Satralizumab in Generalized Myasthenia Gravis

  NeuroFrontiers

  LUMINESCE: Assessing Satralizumab in Generalized Myasthenia Gravis